
Consult your healthcare
provider before using this
product for your heart.
A New Revolution in Aspirin Delivery
The first liquid-filled aspirin capsule.
See what makes Vazalore’s unique formulation different.

The Miracles of Aspirin, Now in a Novel Liquid-filled Capsule
As one of the most widely used drugs in the world, it’s time for a new scientific advancement that allows aspirin to deliver on the cardiovascular benefits so highly sought after. It’s about time that there is a new delivery system for this life-saving immediate release aspirin. One that achieves fast, reliable, predictable antiplatelet activity1 – while causing fewer erosions and ulcers.2* It’s time for Vazalore. A clinical trial showed that Vazalore 325 mg achieved a complete antiplatelet effect (99% inhibition of thromboxane B2 generation) significantly faster than enteric coated aspirin (p<0.0001).3†
*At 7 days versus immediate release aspirin tablets. (See Cryer, et al)
†By 72 hours among obese, diabetic subjects. (See Bhatt, et al)
It’s a Win-Win for Patients AND Doctors
If recommended by your doctor, Vazalore may:
- Provide Heart Attack and Stroke Protection
- Achieve Predictable Antiplatelet Activity1*
- Cause Fewer Erosions and Ulcers2†
*Bioequivalent to immediate release aspirin tablets. (See Angiolillo, et al)
†At 7 days versus immediate release aspirin tablets. (See Cryer, et al)
Doing It Right
Sometimes doing something right requires looking at the problem from a different perspective. It also means we don’t have to accept status quo and we’re willing to buck common misperceptions. At PLx Pharma we did just that – we took a different approach and engineered an innovative and effective platform for the safe delivery of active pharmaceutical ingredients.
Stock Quote
PLXP (Common Stock)
Recent News
References: 1. Angiolillo DJ, Bhatt DL, Lanza F, et al. Pharmacokinetic/pharmacodynamic assessment of a novel, pharmaceutical lipid-aspirin complex: results of a randomized, crossover, bioequivalence study. J Thromb Thrombolysis. 2019;48(4):554-562. 2. Cryer B, Bhatt DL, Lanza FL, et al. Low-dose aspirin-induced ulceration is attenuated by aspirin—phosphatidylcholine: a randomized clinical trial. Am J Gastroenterol. 2011;106(2):272-277. 3. Bhatt DL, Grosser T, Dong JF, et al. Enteric coating and aspirin nonresponsiveness in patients with type 2 diabetes mellitus. JACC. 2017;69(6):603-612.